For the quarter ending 2026-03-31, ARQT made $105,398K in revenue. -$11,765K in net income. Net profit margin of -11.16%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 105,398 | 129,503 | 99,219 | 81,504 |
| Cost of sales | 9,784 | 11,688 | 8,685 | 7,492 |
| Research and development | 30,627 | 20,451 | 19,604 | 19,453 |
| Selling, general, and administrative | 74,076 | 78,977 | 62,404 | 69,170 |
| Total operating expenses | 114,487 | 111,116 | 90,693 | 96,115 |
| Gain from operations | -9,089 | 18,387 | 8,526 | -14,611 |
| Interest income | 2,275 | 8,897 | - | - |
| Interest expense | 4,368 | 3,001 | 3,071 | 3,029 |
| Other income (expense), net | -20 | -6,418 | 2,035 | 2,096 |
| Gain before income taxes | -11,202 | 17,865 | 7,490 | -15,544 |
| Provision for income taxes | 93 | 470 | 80 | 342 |
| Net gain | -11,295 | 17,395 | 7,410 | -15,886 |
| Unrealized loss on marketable securities | -351 | -42 | 68 | -95 |
| Foreign currency translation adjustment | -119 | 60 | -95 | 200 |
| Total other comprehensive gain | -470 | 18 | -27 | 105 |
| Comprehensive gain | -11,765 | 17,413 | 7,383 | -15,781 |
| Basic EPS | -0.09 | 0.136 | 0.06 | -0.13 |
| Diluted EPS | -0.09 | 0.142 | 0.06 | -0.13 |
| Basic Average Shares | 129,365 | 128,279,138 | 127,623,000 | 126,997,000 |
| Diluted Average Shares | 129,365 | 123,017,138 | 132,885,000 | 126,997,000 |
Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics, Inc. (ARQT)